UCB Reports P-III Open-Label Extension Study Results of Fintepla (fenfluramine) for Lennox-Gastaut Syndrome


The P-III OLE study evaluating Fintepla (0.2/0.7mg/kg/day) added to an anti-epileptic treatment regimen vs PBO in 247 patients aged 2-35yrs. with LGSat 65 study sites in North America, the EU & Australia
The results showed a reduction in the frequency of multiple seizure types associated with a drop or fall for 15mos. incl. tonic & generalized tonic-clonic seizures & was well tolerated during a median treatment duration of 364 days. The results were published in Epilepsia
Median percentage change in monthly drop seizure frequency (-28.6% vs -50.5%) @15mos. with 31.1% experiencing a ≥50% reduction, change in frequency of all motor seizures was 45.9%. GTCS & tonic seizures were most responsive to treatment with median reductions over the entire OLE of -48.8% & -35.8%

Ref: PRNewswire | Image: UCB